- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.11. | Virax BioLabs Group Limited: Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes | 173 | PR Newswire | LONDON, Nov. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection... ► Artikel lesen | |
| 01.09. | Virax Biolabs Collaborating With Emory University On Clinical Studies | 1 | pulse2.com | ||
| 27.08. | Virax Biolabs (VRAX) Falls 18% on Lack of Leads | 1 | Insider Monkey | ||
| 26.08. | Virax Biolabs partners with Emory for long COVID diagnostic studies | 1 | Investing.com | ||
| 26.08. | Virax Biolabs startet mit Emory University Studien zur Long-COVID-Diagnostik | 1 | Investing.com Deutsch | ||
| VIRAX BIOLABS GROUP Aktie jetzt für 0€ handeln | |||||
| 26.08. | Virax BioLabs Group Limited: Virax Biolabs Partners with Emory University on ViraxImmune Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September | 163 | PR Newswire | LONDON, Aug. 26, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immune... ► Artikel lesen | |
| 26.08. | EXCLUSIVE: Virax Biolabs Inks Research Pact To Advance Long COVID Diagnostic Studies | 2 | Benzinga.com | ||
| 30.07. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 29.07. | Virax Biolabs appoints Iain Miller as independent director | 1 | Investing.com | ||
| 18.07. | Virax Biolabs receives Nasdaq minimum bid price deficiency notice | 1 | Investing.com | ||
| 18.07. | Virax Biolabs receives Nasdaq letter over non-compliance with minimum bid price rule | 5 | Seeking Alpha | ||
| 18.07. | Virax BioLabs Group Limited: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency | 194 | PR Newswire | LONDON, July 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the... ► Artikel lesen | |
| 02.07. | Virax Biolabs Group Ltd - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 13.06. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.03. | Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes | 204 | PR Newswire | LONDON, March 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on... ► Artikel lesen | |
| 23.01. | Cosmos Health Inc.: Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait | 584 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 13.01. | Cosmos Health Inc.: Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries | 430 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 84,05 | +0,18 % | BioNTech Aktie: Starke Unterstützungen und eine Kaufempfehlung | Berichte, dass Pfizer seine Beteiligung an BioNTech reduziere, haben den Aktienkurs des Mainzer Biotech-Unternehmens zuletzt spürbar fallen lassen. An der NASDAQ wurden gestern 94 Dollar erreicht. Am... ► Artikel lesen | |
| EVOTEC | 5,630 | -2,93 % | Evotec Aktie: Starke Kursbewegungen könnten bevor stehen! | Immerhin: Die Evotec Aktie konnte vom gestrigen Auftritt des Unternehmens auf dem Eigenkapitalforum der Deutschen Börse in Frankfurt zwar keine großen Gewinne erzielen, aber ein leichtes Plus im freundlichen... ► Artikel lesen | |
| ASEP MEDICAL | 6,021 | -100,00 % | ASEP Medical Holdings Inc (2): ASEP licenses anti-biofilm peptide tech to Bondent | ||
| GINKGO BIOWORKS | 7,800 | +4,00 % | Ginkgo Bioworks Reports Third Quarter 2025 Financial Results | Ginkgo provides an update on its third quarter financial results
BOSTON, Nov. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today... ► Artikel lesen | |
| AGIOS | 23,800 | -1,65 % | Cantor Fitzgerald bestätigt "Overweight"-Rating für Agios Pharma Aktie | ||
| GENPREX | 2,800 | 0,00 % | Genprex, Inc. - S-1/A, General form for registration of securities | ||
| PALISADE BIO | 1,855 | -12,09 % | Palisade Bio, Inc.: Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations | Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications Company remains focused on... ► Artikel lesen | |
| GEOVAX LABS | 0,376 | 0,00 % | GeoVax Labs, Inc. - 8-K, Current Report | ||
| ANNOVIS BIO | 3,850 | -0,77 % | Annovis Bio Inc.: Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment | MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen | |
| HUMACYTE | 1,280 | -5,19 % | Humacyte stock rating reiterated at Buy by H.C. Wainwright | ||
| SAGIMET BIOSCIENCES | 5,850 | -0,85 % | Sagimet Biosciences Inc.: Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates | Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567... ► Artikel lesen | |
| QIAGEN | 40,985 | -0,34 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,36 | -0,47 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,370 | +0,99 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| JANUX THERAPEUTICS | 33,970 | 0,00 % | Janux-Aktie bricht nach Studiendaten nachbörslich um 26 % ein |
VIRAX BIOLABS GROUP LIMITED gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,006 (+1,44 %) liegt der Kurs bei 0,396 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIRAX BIOLABS GROUP LIMITED finden Sie auf Wallstreet Online.